CLDX - Celldex Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.7900
-0.1700 (-4.29%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.9600
Open3.9600
Bid3.8400 x 800
Ask4.1000 x 1200
Day's Range3.7300 - 4.0400
52 Week Range2.7000 - 12.6000
Volume405,027
Avg. Volume2,175,203
Market Cap47.146M
Beta (3Y Monthly)5.61
PE Ratio (TTM)N/A
EPS (TTM)-14.4780
Earnings DateMay 8, 2019 - May 13, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.00
Trade prices are not sourced from all markets
  • Celldex (CLDX) Down 5.7% Since Last Earnings Report: Can It Rebound?
    Zacks14 days ago

    Celldex (CLDX) Down 5.7% Since Last Earnings Report: Can It Rebound?

    Celldex (CLDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • GlobeNewswire18 days ago

    Celldex Presents Positive Interim Results from Phase 1 Study of CD40 Agonist CDX-1140 at American Association for Cancer Research (AACR) Annual Meeting 2019

    Celldex Therapeutics, Inc. (CLDX) presented interim data from the Company’s CD40 agonist program in a late-breaking poster session today at the American Association for Cancer Research (AACR) Annual Meeting 2019. CD40, expressed on dendritic cells and other antigen presenting cells, is an important target for immunotherapy, as it plays a critical role in the activation of innate and adaptive immune responses.CDX-1140 is a fully human agonist anti-CD40 monoclonal antibody that was specifically designed to balance good systemic exposure and safety with potent biological activity, a profile which differentiates CDX-1140 from other CD40-activating antibodies.

  • GlobeNewswire19 days ago

    Celldex Presents Promising Data from CDX-527 Bispecific and TAM Receptor Programs at American Association for Cancer Research (AACR) Annual Meeting 2019

    Celldex Therapeutics, Inc. (CLDX) presented promising data from the Company’s growing bispecific and TAM (Tyro3, Axl, MerTK) receptor programs during poster sessions today at the American Association for Cancer Research (AACR) Annual Meeting 2019. “Our research and discovery efforts have yielded multiple promising candidates that address important needs in cancer immunotherapy and complement our pipeline,” said Tibor Keler, Ph.D., Executive Vice President and Chief Scientific Officer of Celldex Therapeutics. “CDX-527 joins two powerful pathways in the immune system, PD-1 blockade and CD27 costimulation.

  • Is Celldex Therapeutics (CLDX) Stock Outpacing Its Medical Peers This Year?
    Zackslast month

    Is Celldex Therapeutics (CLDX) Stock Outpacing Its Medical Peers This Year?

    Is (CLDX) Outperforming Other Medical Stocks This Year?

  • Thomson Reuters StreetEventslast month

    Edited Transcript of CLDX earnings conference call or presentation 7-Mar-19 9:30pm GMT

    Q4 2018 Celldex Therapeutics Inc Earnings Call

  • Celldex (CLDX) Q4 Loss Narrower than Expected, Sales Beat
    Zackslast month

    Celldex (CLDX) Q4 Loss Narrower than Expected, Sales Beat

    Celldex (CLDX) reports narrower-than-expected loss, while sales miss estimates in the fourth quarter of 2018.

  • Celldex Therapeutics' Cost-Cutting and Reverse Stock Split Help Keep It Rolling
    Motley Foollast month

    Celldex Therapeutics' Cost-Cutting and Reverse Stock Split Help Keep It Rolling

    The clinical-stage biotech stretched out its cash in the fourth quarter by cost reductions and took the necessary moves in the following months to retain its listing on the Nasdaq stock exchange.

  • Celldex Therapeutics, Inc (CLDX) Q4 2018 Earnings Conference Call Transcript
    Motley Foollast month

    Celldex Therapeutics, Inc (CLDX) Q4 2018 Earnings Conference Call Transcript

    CLDX earnings call for the period ending December 31, 2018.

  • GlobeNewswirelast month

    Celldex Provides Corporate Update and Reports Full Year 2018 Results

    HAMPTON, N.J., March 07, 2019 -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the fourth quarter and year ended December 31,.

  • Benzingalast month

    Daily Biotech Pulse: Allergan's Depression Drug Flunks Late-Stage Trial, Apellis Offering, ShockWave Medical IPO

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on March 6) Chiasma Inc (NASDAQ: CHMA ) Magenta Therapeutics Inc ...

  • Celldex Therapeutics (CLDX) Stock Sinks As Market Gains: What You Should Know
    Zacks2 months ago

    Celldex Therapeutics (CLDX) Stock Sinks As Market Gains: What You Should Know

    In the latest trading session, Celldex Therapeutics (CLDX) closed at $5.92, marking a -1.17% move from the previous day.

  • GlobeNewswire2 months ago

    Analysis: Positioning to Benefit within Applied Materials, MRC Global, Meritor, Celldex Therapeutics, Quaker Chemical, and Cubic — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Feb. 20, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.

  • The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna
    Zacks2 months ago

    The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna

    The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna

  • 5 Tiny Biotech Stocks With Superb Growth Potential
    Zacks2 months ago

    5 Tiny Biotech Stocks With Superb Growth Potential

    A spurt in deal-making has boosted the sector this year which retains the ability to provide outsized gains.

  • Benzinga2 months ago

    The Celldex Reverse Stock Split: What Investors Need To Know

    Celldex Therapeutics, Inc. (NASDAQ: CLDX) stock tanked Monday after the company effected a 15-to-1 reverse stock split that was first announced two days ago. The reverse split pushed Celldex’s share price from about 39 cents to about $5 per share, but the market’s negative initial reaction to the decision is typical of the response to reverse splits. Celldex was forced into the aggressive reverse split after the stock crashed 84 percent in the past year as the market lost its optimism about immunotherapy combination treatments.

  • ACCESSWIRE2 months ago

    Biotech Stocks To Watch

    HENDERSON, NV / ACCESSWIRE / February 11, 2019 / Investing in biotech companies can provide investors with huge gains. With that in mind, we're highlighting a few you should know about. One you should ...

  • GlobeNewswire2 months ago

    Celldex Therapeutics Announces Reverse Stock Split

    Celldex Therapeutics, Inc. (CLDX) (“Celldex” or the “Company”) today announced that its Board of Directors has approved a one-for-fifteen reverse stock split of its common stock that became effective today upon the filing with the Secretary of the State of Delaware a Certificate of Amendment to its Certificate of Incorporation. Beginning on February 11, 2019, Celldex’s common stock will trade on the Nasdaq Capital Market on a split-adjusted basis under the new CUSIP number 15117B202. As previously disclosed, at the Company’s Annual Meeting of Stockholders held on June 13, 2018, Celldex stockholders approved a proposal authorizing the Company’s Board of Directors to effect a reverse stock split by a ratio of not less than one-for-ten and not more than one-for-fifteen.

  • ACCESSWIRE2 months ago

    4 Healthcare Stocks The Market is Watching on Tuesday (2/5/19)

    CORAL GABLES, FL / ACCESSWIRE / February 5, 2019 / The healthcare stock market has been a hotbed of excitement over the course of the past couple of years as companies across the healthcare industry have employed more nuanced approaches to how they offer care to patients. With the advent of new medical technologies and approaches to treating patients suffering from a myriad of diseases, news surrounding innovative companies putting their skills to the test in the healthcare industry has worked to attract investors looking for potential opportunities in the space. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Moleculin Biotech Inc (MBRX), Celldex Therapeutics Inc (CLDX), and Teladoc Health Inc (TDOC) represent four healthcare companies focused on innovating towards the future of healthcare.

  • ACCESSWIRE2 months ago

    Biotech Stocks to Watch

    HENDERSON, NV / ACCESSWIRE / February 5, 2019 / Some consider the small-cap and mid-cap - ''smid-cap'' - zone with market caps of $5 billion or less, a bit risky. They aren't wrong. However, if you can ...

  • ACCESSWIRE2 months ago

    These 4 Tech Stocks Could Set February Highs

    CORAL GABLES, FL / ACCESSWIRE / February 4, 2019 / The future of the tech stock market will depend on two key factors: tech experts must continue to work to design and manufacture top-of-the-line products meant to elevate the human experience, and consumers must feel like these new pieces of tech will actually serve a significant purpose in their lives. ParcelPal Technology Inc (PTNYF) (PKG), Maxwell Technologies Inc (MXWL), Top Image Systems Ltd (TISA), and Celldex Therapeutics Inc (CLDX) represent four companies determined to utilize advanced technological solutions to improve the quality of life for consumers on a global scale. ParcelPal Technology Inc (PTNYF) (PKG), along with other companies in the space, is taking advantage of the fact that, as new technologies have been developed to meet the growing challenges in life, so too has the willingness of consumers to be persuadable, in terms of considering products they otherwise might not consider.

  • ACCESSWIRE3 months ago

    Cannabis and Biotech Stocks that Could Explode

    HENDERSON, NV / ACCESSWIRE / January 29, 2019 / Small cap securities in the biotechnology industry are always of interest to investors because several events can help increase the stock's share price at ...

  • ACCESSWIRE3 months ago

    Best Ways to Play Biotech Rally

    HENDERSON, NV / ACCESSWIRE / January 23, 2019 / The market reached a level toward the end of last year where investors and analysts were throwing the "R" word (recession) around. The cause of ...

  • ACCESSWIRE3 months ago

    A Biotech Play You Can't Afford To Miss

    HENDERSON, NV / ACCESSWIRE / January 21, 2019 / Biotechnology companies have seen a ton of interest from Big Pharma so far in 2019. While it's not easy to project who may be next, there are several biotech ...

  • Here's Why Celldex Therapeutics Sank on Friday
    Motley Fool4 months ago

    Here's Why Celldex Therapeutics Sank on Friday

    A rotten week for biotech didn't end well for Celldex.

  • Why Celldex Therapeutics Is Jumping Today
    Motley Fool4 months ago

    Why Celldex Therapeutics Is Jumping Today

    There's nothing to get excited about with this clinical-stage biotech stock's double-digit-percentage gain.